Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation
Standard
Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation : a health economic analysis from a German perspective. / Cremaschi, Liana; von Versen, Regina; Benzing, Thomas; Wiesener, Michael; Zink, Nikolai; Milkovich, Gary; Paivanas, Thomas; Gallagher, Meghan; Thaiss, Friedrich.
in: TRANSPL INT, Jahrgang 30, Nr. 10, 10.2017, S. 1011-1019.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation
T2 - a health economic analysis from a German perspective
AU - Cremaschi, Liana
AU - von Versen, Regina
AU - Benzing, Thomas
AU - Wiesener, Michael
AU - Zink, Nikolai
AU - Milkovich, Gary
AU - Paivanas, Thomas
AU - Gallagher, Meghan
AU - Thaiss, Friedrich
N1 - © 2017 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
PY - 2017/10
Y1 - 2017/10
N2 - A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus basiliximab, in kidney transplantation using resource utilization data and cost estimates from three German hospitals. A three-state Markov model was applied to estimate cost-effectiveness to 10 years post-transplant. Total mean treatment cost per patient to year 1 post-transplant was €62 075 vs. €59 767 for rATG versus basiliximab (P < 0.01). rATG therapy was associated with similar treatment costs to basiliximab by year 2, and a predicted cumulative treatment cost saving of €4 259 under rATG versus basiliximab by year 10 post-transplant. The mean number of quality-adjusted life years (QALYs) per patient by year 1 was 0.809 vs. 0.802 in the rATG and basiliximab cohorts, respectively (P = 0.38), with cumulative QALYs of 6.161 and 6.065 per patient by year 10. By year 2, the cumulative cost per QALY was slightly lower under rATG (€35 378) than basiliximab (€35 885), progressing to a saving of €1 041 under rATG for the cumulative cost per QALY by year 10. In conclusion, this model indicates that rATG induction provides a modest increase in QALYs with lower long-term costs than basiliximab in deceased-donor high-risk kidney transplant patients.
AB - A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus basiliximab, in kidney transplantation using resource utilization data and cost estimates from three German hospitals. A three-state Markov model was applied to estimate cost-effectiveness to 10 years post-transplant. Total mean treatment cost per patient to year 1 post-transplant was €62 075 vs. €59 767 for rATG versus basiliximab (P < 0.01). rATG therapy was associated with similar treatment costs to basiliximab by year 2, and a predicted cumulative treatment cost saving of €4 259 under rATG versus basiliximab by year 10 post-transplant. The mean number of quality-adjusted life years (QALYs) per patient by year 1 was 0.809 vs. 0.802 in the rATG and basiliximab cohorts, respectively (P = 0.38), with cumulative QALYs of 6.161 and 6.065 per patient by year 10. By year 2, the cumulative cost per QALY was slightly lower under rATG (€35 378) than basiliximab (€35 885), progressing to a saving of €1 041 under rATG for the cumulative cost per QALY by year 10. In conclusion, this model indicates that rATG induction provides a modest increase in QALYs with lower long-term costs than basiliximab in deceased-donor high-risk kidney transplant patients.
KW - Animals
KW - Antibodies, Monoclonal
KW - Antilymphocyte Serum
KW - Basiliximab
KW - Humans
KW - Immunosuppressive Agents
KW - Induction Chemotherapy
KW - Kidney Transplantation
KW - Middle Aged
KW - Quality-Adjusted Life Years
KW - Rabbits
KW - Recombinant Fusion Proteins
KW - Comparative Study
KW - Journal Article
KW - Randomized Controlled Trial
U2 - 10.1111/tri.12991
DO - 10.1111/tri.12991
M3 - SCORING: Journal article
C2 - 28556488
VL - 30
SP - 1011
EP - 1019
JO - TRANSPL INT
JF - TRANSPL INT
SN - 0934-0874
IS - 10
ER -